WO2002039947A3 - Vecteurs de transport a travers un epithelium a jonctions serrees - Google Patents

Vecteurs de transport a travers un epithelium a jonctions serrees Download PDF

Info

Publication number
WO2002039947A3
WO2002039947A3 PCT/FR2001/003631 FR0103631W WO0239947A3 WO 2002039947 A3 WO2002039947 A3 WO 2002039947A3 FR 0103631 W FR0103631 W FR 0103631W WO 0239947 A3 WO0239947 A3 WO 0239947A3
Authority
WO
WIPO (PCT)
Prior art keywords
epithelium
tight junctions
carrier vectors
vectors
carrier
Prior art date
Application number
PCT/FR2001/003631
Other languages
English (en)
Other versions
WO2002039947A2 (fr
Inventor
Alain Joliot
Edmond Dupont
Alain Prochiantz
Original Assignee
Centre Nat Rech Scient
Alain Joliot
Edmond Dupont
Alain Prochiantz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Alain Joliot, Edmond Dupont, Alain Prochiantz filed Critical Centre Nat Rech Scient
Priority to US10/432,291 priority Critical patent/US8242088B2/en
Priority to CA2427896A priority patent/CA2427896C/fr
Priority to EP01996347.9A priority patent/EP1351648B1/fr
Priority to JP2002542322A priority patent/JP4860896B2/ja
Priority to AU2002221994A priority patent/AU2002221994A1/en
Publication of WO2002039947A2 publication Critical patent/WO2002039947A2/fr
Publication of WO2002039947A3 publication Critical patent/WO2002039947A3/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation de vecteurs peptidiques, comprenent un domaine de transduction, et une séquence d'export nucléaire, pour transporter une molécule d'intérêt à travers un épithélium à jonctions serrées, tel que la barrière hémato-méningée.
PCT/FR2001/003631 2000-11-20 2001-11-20 Vecteurs de transport a travers un epithelium a jonctions serrees WO2002039947A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/432,291 US8242088B2 (en) 2000-11-20 2001-11-20 Carrier vectors through an epithelium with tight junctions
CA2427896A CA2427896C (fr) 2000-11-20 2001-11-20 Vecteurs de transport a travers un epithelium a jonctions serrees
EP01996347.9A EP1351648B1 (fr) 2000-11-20 2001-11-20 Vecteurs de transport a travers un epithelium a jonctions serrees
JP2002542322A JP4860896B2 (ja) 2000-11-20 2001-11-20 密着結合した上皮を介した担体ベクター
AU2002221994A AU2002221994A1 (en) 2000-11-20 2001-11-20 Carrier vectors through an epithelium with tight junctions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0014945A FR2816845B1 (fr) 2000-11-20 2000-11-20 Vecteurs de transport a travers un epithelium a jonctions serrees
FR00/14945 2000-11-20

Publications (2)

Publication Number Publication Date
WO2002039947A2 WO2002039947A2 (fr) 2002-05-23
WO2002039947A3 true WO2002039947A3 (fr) 2003-07-17

Family

ID=8856657

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/003631 WO2002039947A2 (fr) 2000-11-20 2001-11-20 Vecteurs de transport a travers un epithelium a jonctions serrees

Country Status (7)

Country Link
US (1) US8242088B2 (fr)
EP (1) EP1351648B1 (fr)
JP (1) JP4860896B2 (fr)
AU (1) AU2002221994A1 (fr)
CA (1) CA2427896C (fr)
FR (1) FR2816845B1 (fr)
WO (1) WO2002039947A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060062758A1 (en) * 2004-09-21 2006-03-23 Nastech Pharmaceutical Comapny Inc. Tight junction modulator peptide PN159 for enhanced mucosal delivery of therapeutic compounds
DK1988167T3 (da) * 2005-02-17 2020-07-13 Univ Sorbonne Intracellulære inhiberende peptider
FR2897780B1 (fr) 2006-02-28 2008-05-23 Centre Nat Rech Scient Utilisation de la proteine a homeodomaine engrailed comme anxiolytique
US20120020996A1 (en) 2008-08-06 2012-01-26 Jonathan Lewis Telfer Vaccines against clostridium difficile and methods of use
CN101993495B (zh) * 2009-08-12 2013-07-24 上海近岸科技有限公司 一种蛋白质混合物及其制备方法
US8916679B2 (en) 2009-12-01 2014-12-23 Universita′ degli Studi di Modena e Reggio Emilia Peptides binding to the dimer interface of thymidylate synthase for the treatment of cancer
WO2014194259A1 (fr) * 2013-05-30 2014-12-04 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Procédés et compositions pour traiter des maladies cérébrales
US11752315B1 (en) 2016-10-07 2023-09-12 Carlos A. Hakim Method of treating normal pressure hydrocephalus
EP3309260A1 (fr) * 2016-10-14 2018-04-18 European Molecular Biology Laboratory Synthétase trna pyrrolysine archéale pour utilisation orthogonale

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999005302A1 (fr) * 1997-07-24 1999-02-04 The Perkin-Elmer Corporation Conjugues de peptides transporteurs et analogues d'acides nucleiques ainsi que leur utilisation
WO2000029427A2 (fr) * 1998-11-13 2000-05-25 Cyclacel Limited Vecteurs de transport
WO2000058488A2 (fr) * 1999-03-31 2000-10-05 Invitrogen Corporation Diffusion de sequences de proteines fonctionnelles par translocation de polypeptides
WO2000062067A1 (fr) * 1999-02-28 2000-10-19 Washington University Nouvelles molecules de transduction et leurs procedes d'utilisation
WO2001013957A2 (fr) * 1999-08-24 2001-03-01 Cellgate, Inc. Compositions et procedes ameliorant la diffusion de medicaments a travers et dans des tissus epitheliaux
WO2001038547A2 (fr) * 1999-11-24 2001-05-31 Mcs Micro Carrier Systems Gmbh Polypeptides comprenant des multimeres de signaux de localisation nucleaire ou de domaines de transduction de proteine et utilisations de ces derniers pour transferer des molecules dans des cellules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888762A (en) 1990-06-05 1999-03-30 Centre National De La Recherche Scientifique (Cnrs) Neurotropic growth factors comprising a homeobox peptide
FR2739621B1 (fr) 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
US6773920B1 (en) * 1999-03-31 2004-08-10 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
US6472176B2 (en) * 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999005302A1 (fr) * 1997-07-24 1999-02-04 The Perkin-Elmer Corporation Conjugues de peptides transporteurs et analogues d'acides nucleiques ainsi que leur utilisation
WO2000029427A2 (fr) * 1998-11-13 2000-05-25 Cyclacel Limited Vecteurs de transport
WO2000062067A1 (fr) * 1999-02-28 2000-10-19 Washington University Nouvelles molecules de transduction et leurs procedes d'utilisation
WO2000058488A2 (fr) * 1999-03-31 2000-10-05 Invitrogen Corporation Diffusion de sequences de proteines fonctionnelles par translocation de polypeptides
WO2001013957A2 (fr) * 1999-08-24 2001-03-01 Cellgate, Inc. Compositions et procedes ameliorant la diffusion de medicaments a travers et dans des tissus epitheliaux
WO2001038547A2 (fr) * 1999-11-24 2001-05-31 Mcs Micro Carrier Systems Gmbh Polypeptides comprenant des multimeres de signaux de localisation nucleaire ou de domaines de transduction de proteine et utilisations de ces derniers pour transferer des molecules dans des cellules

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BELLET-AMALRIC E ET AL: "INTERACTION OF THE THIRD HELIX OF ANTENNAPEDIA HOMEODOMAIN AND A PHOSPHOLIPID MONOLAYER, STUDIED BY ELLIPSOMETRY AND PM-IRRAS AT THEAIR-WATER INTERFACE", BIOCHIMICA ET BIOPHYSICA ACTA, AMSTERDAM, NL, vol. 1467, no. 1, 31 July 2000 (2000-07-31), pages 131 - 143, XP001004550, ISSN: 0006-3002 *
DATHE, MARGITTA ET AL: "Peptide Helicity and Membrane Surface Charge Modulate the Balance of Electrostatic and Hydrophobic Interactions with Lipid Bilayers and Biological Membranes", BIOCHEMISTRY, 1996, VOL. 35, NO. 38, PAGE(S) 12612-12622, XP002176664 *
DEROSSI D (REPRINT) ET AL: "Trojan peptides: the penetratin system for intracellular delivery", TRENDS IN CELL BIOLOGY, vol. 8, February 1998 (1998-02-01), pages 84 - 87, XP002122131, ISSN: 0962-8924 *
FISCHER P M ET AL: "STRUCTURE-ACTIVITY RELATIONSHIP OF TRUNCATED AND SUBSTITUTED ANALOGUES OF THE INTRACELLULAR DELIVERY VECTOR PENETRATIN", JOURNAL OF PEPTIDE RESEARCH, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 55, no. 2, February 2000 (2000-02-01), pages 163 - 172, XP000899124, ISSN: 1397-002X *
JAEGER E A: "Small synthetic peptides homologous to segments of occludin impair tight junction resealing in a Ca2+-switch assay in A6 cell monolayers", MOLECULAR BIOLOGY OF THE CELL, vol. 8, suppl., November 1997 (1997-11-01), & 37th Annual Meeting of the American Society for Cell Biology; Washington, D.C., USA; December 13-17, 1997, pages 205A, abrégé no. 1189, XP002099341, ISSN: 1059-1524 *
OEHLKE, J. ET AL: "Rapid translocation of amphipathic alpha-helical and beta-sheet-forming peptides through plasma membranes of endothelial cells", PEPT. SCI.: PRESENT FUTURE, PROC. INT. PEPT. SYMP., 1ST, 1999, VOL. MEETING DATE 1997, 782-783. EDITOR(S): SHIMONISHI, YASUTSUGU. PUBLISHER: KLUWER, DORDRECHT, NETH., XP001016351 *
PROCHIANTZ A: "Getting hydrophilic compounds into cells: lessons from homeopeptides", CURRENT OPINION IN NEUROBIOLOGY, LONDON, GB, vol. 6, no. 5, 1 October 1996 (1996-10-01), pages 629 - 634, XP002087113, ISSN: 0959-4388 *
ROUSSELLE C ET AL: "NEW ADVANCES IN THE TRANSPORT OF DOXORUBICIN THROUGH THE BLOOD-BRAIN BARRIER BY A PEPTIDE VECTOR-MEDIATED STRATEGY", MOLECULAR PHARMACOLOGY, BALTIMORE, MD, US, vol. 57, no. 4, April 2000 (2000-04-01), pages 679 - 686, XP001004535, ISSN: 0026-895X *
SCHELLER, ANNE ET AL: "Structural requirements for cellular uptake of.alpha.-helical amphipathic peptides", J. PEPT. SCI., 1999, VOL. 5, NO. 4, PAGE(S) 185-194, XP001016347 *
SCHWARZE S ET AL: "In vivo protein transduction: delivery of a biologically active protein into the mouse", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 285, no. 5433, 3 September 1999 (1999-09-03), pages 1569 - 1572, XP002140133, ISSN: 0036-8075 *
THOREN P E G ET AL: "THE ANTENNAPEDIA PEPTIDE PENETRATIN TRANSLOCATES ACROSS LIPID BILAYERS - THE FIRST DIRECT OBSERVATION", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 482, no. 3, 6 October 2000 (2000-10-06), pages 265 - 268, XP001004487, ISSN: 0014-5793 *

Also Published As

Publication number Publication date
US8242088B2 (en) 2012-08-14
EP1351648A2 (fr) 2003-10-15
EP1351648B1 (fr) 2014-04-16
CA2427896A1 (fr) 2002-05-23
AU2002221994A1 (en) 2002-05-27
JP4860896B2 (ja) 2012-01-25
WO2002039947A2 (fr) 2002-05-23
JP2004526670A (ja) 2004-09-02
FR2816845A1 (fr) 2002-05-24
FR2816845B1 (fr) 2006-10-20
US20040029281A1 (en) 2004-02-12
CA2427896C (fr) 2014-01-07

Similar Documents

Publication Publication Date Title
WO2003031464A3 (fr) Remodelage et glycoconjugaison de peptides
AU2002323413A1 (en) Playlist generation, delivery and navigation
WO2001075067A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001057190A3 (fr) Acides nucleiques et polypeptides
WO2002022660A3 (fr) Noveaux acides nucleiques et polypeptides
WO2001066689A3 (fr) Nouveaux acides nucleiques et polypeptides
AU2002248136A1 (en) Cloning vectors and vector components
WO2002031111A3 (fr) Acides nucleiques et polypeptides
WO2002086083A3 (fr) Procedes d'amelioration de la capacite de reaction de cellules t
WO2001053455A3 (fr) Nouveaux acides nucleiques et polypeptides associes
WO2001088088A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002059260A3 (fr) Nouveaux acides nucleiques et polypeptides
ZA200107496B (en) Amine derivatives as protease inhitors.
WO2001030371A3 (fr) Peptides analgesiants chimeriques
AU2001249533A1 (en) Wafer carrier head assembly
WO2002039947A3 (fr) Vecteurs de transport a travers un epithelium a jonctions serrees
WO1999003881A3 (fr) Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
EP1818062A3 (fr) Anticorps anti HSP90
AU2002301199A1 (en) Strapping machines with improved refeed
AU2686099A (en) Cyclic peptide antifungal agents
WO2002018424A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001079449A3 (fr) Acides nucleiques et polypeptides nouveaux
CA2361987A1 (fr) Proteine de liaison a l'antigene du syndrome de goodpasture
WO2002044232A8 (fr) Polyanhydrides
IL139604A0 (en) Novel peptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2427896

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001996347

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002542322

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 10432291

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001996347

Country of ref document: EP